Physician

Marie Michelle Amanze, MD

According to 2025 Medicare claims, Marie Amanze, MD (NPI: 1740383181) practices hematology/oncology in the Tallahassee, FL market, with the plurality of this provider's patient population coming from Leon, FL. This provider's primary affiliated billing organization is HEMATOLOGY ONCOLOGY SOLUTIONS OF TALLAHASSEE LLC (NPI: 1972862555; TIN: 45-5170842) and primary practice location at 32308-5478.

Amanze's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 172 traditional Medicare patients, billed 97,072 HCPCS/CPT codes, and received $891,696 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,414 prescription claims across 184 beneficiaries totaling $3,590,212 in drug costs, led by Pomalyst (Pomalidomide). 2023 DME data shows 24 claims. Open Payments data shows 1 records totaling $6. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $534,116 to $891,696. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $730,262 to $3,590,212. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,284 to $1,507.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	205	55,446	$534,116
2016	215	65,684	$622,687
2017	205	78,425	$988,568
2018	200	90,499	$1,138,020
2019	215	90,311	$1,381,238
2020	217	132,576	$1,854,998
2021	196	68,355	$1,290,793
2022	180	71,810	$1,094,665
2023	176	83,079	$899,695
2024	172	97,072	$891,696

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	168	1,704	$730,262
2016	177	1,615	$1,119,364
2017	169	1,766	$1,507,488
2018	169	1,544	$1,761,220
2019	174	1,421	$1,763,680
2020	176	1,583	$2,784,087
2021	185	1,406	$3,119,029
2022	187	1,434	$3,386,914
2023	195	1,526	$4,084,792
2024	184	1,414	$3,590,212

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	54	$4,957
2016	N/R	N/R	N/R
2017	N/R	11	$454
2018	N/R	30	$1,168
2019	N/R	35	$798
2020	N/R	N/R	N/R
2021	N/R	22	$1,140
2022	N/R	N/R	N/R
2023	N/R	24	$1,507
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	130	260	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	121	237	$65
36415	Insertion of needle into vein for collection of blood sample	144	547	$9
85027	Complete blood cell count (red cells, white blood cell, platelets), automated test	142	502	$6
J7050	Infusion, normal saline solution, 250 cc	55	534	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	65	1,820	$1,250,390
Calquence	Acalabrutinib Maleate	30	900	$450,382
Lenalidomide	Lenalidomide	30	840	$332,819
Alecensa	Alectinib Hcl	11	330	$210,046
Revlimid	Lenalidomide	13	364	$201,463

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$6	Rigel Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Marie Michelle Amanze, MD?

Tedicare shows public-source Medicare data for Marie Michelle Amanze, MD (NPI 1740383181), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Marie Michelle Amanze, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Marie Michelle Amanze, MD?

Marie Michelle Amanze, MD is linked to HEMATOLOGY ONCOLOGY SOLUTIONS OF TALLAHASSEE LLC (billing NPI 1972862555) in the available physician profile data.

Does Marie Michelle Amanze, MD have Open Payments data?

Marie Michelle Amanze, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.